|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||64.15 - 67.05|
|52-week range||17.50 - 74.30|
|PE ratio (TTM)||N/A|
|Earnings date||20 Feb 2018 - 26 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||53.67|
Foundation Medicine, Inc. today announced that the company has entered into a broad partnership with Pfizer Inc. . The partnership focuses on development, regulatory support and commercialization of companion diagnostics that will be included in updates to FoundationOne CDx™.
Foundation Medicine today announced preliminary unaudited total revenue of approximately $48.9 million for the fourth quarter of 2017 and approximately $152.9 million for the full year ended December 31, 2017, representing a 70% and 31% increase from the $28.8 million and $116.9 million recorded in the fourth quarter and full year ended December 31, 2016, respectively.
Foundation Medicine today announced that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 3:30 p.m.
Foundation Medicine, Inc. today announced that new data generated with FoundationOne®Heme, its comprehensive genomic profiling assay for hematologic malignancies and sarcomas, will be presented at the American Society of Hematology Annual Meeting.
Michael Pellini, chairman of genomic diagnostics company Foundation Medicine Inc., has joined Section 32 as a managing partner.
Ex-Google Ventures head Bill Maris is deepening his firm’s health-care expertise, hiring Foundation Medicine Inc. Chairman Michael Pellini to join him at Section 32.
ZURICH (Reuters) - Roche (ROG.S) on Monday said its Foundation Medicine (FMI.O) unit won U.S. Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients' ...
Determining which cancer drugs will work best in each individual patient could become easier following this important FDA approval.
The government approved the company's new test that finds flaws in 324 genes that can drive cancer growth. Foundation Medicine shares (FMI) rose 18% today, on 14-times recent average volumes, to close at $62.60. Medicare and Medicaid administrators also indicated their willingness to cover the test, which Foundation calls FoundationOne CDx. Foundation says it will help identify patients who might benefit from any of 17 targeted therapies, as well as newer immunotherapies.
Foundation Medicine hit a high after U.S. regulators approved its test to match cancer patients to FDA-approved therapies.
Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration approved FoundationOne CDx™, the company’s comprehensive companion diagnostic test for solid tumors.
Investors in Foundation Medicine (FMI) need to pay close attention to the stock based on moves in the options market lately.
Cancer treatment is moving rapidly toward personalized medicine and precision medicine thanks to genetic insight.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 90 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Foundation Medicine, Inc. today reported financial and operating results for its third quarter ended September 30, 2017. Results and business highlights for the quart
Foundation Medicine, Inc. today announced that the company will present validation data for FoundationOne CDx, its comprehensive genomic profiling assay, at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer .
Foundation Medicine, Inc. today announced that financial results for the company's third quarter ended September 30, 2017 will be released on Wednesday, November 1, 2017.
Foundation Medicine, Inc. today announced the appointment of Tom Civik to the role of chief commercial officer. Mr. Civik brings to Foundation Medicine more than two decades of commercial and operational experience with global biopharmaceutical organizations, most recently having served as a vice president and officer for Genentech, as well as previously serving in increasingly complex commercial positions ...
Foundation Medicine, Inc. today announced that it received approval from the New York State Clinical Laboratory Evaluation Program for its FoundationACT® blood-based circulating tumor DNA assay.
Foundation Medicine, Inc. (NASDAQ:FMI) today announced presentations at the European Society for Medical Oncology (ESMO) Annual Meeting highlighting validation data for its novel assay to measure tumor mutational burden from blood (bTMB). The studies demonstrate that high bTMB as measured by Foundation Medicine’s assay is associated with response to atezolizumab in individuals with previously-treated non-small cell lung cancer (NSCLC), potentially offering a new option to expand personalized care options for patients with advanced cancer. Based on these findings, Foundation Medicine also announced today that its bTMB assay will be integrated as part of Roche/Genentech’s prospective, randomized Phase III Blood First Assay Screening Trial (BFAST) as a companion diagnostic assay to investigate bTMB as a non-invasive biomarker of response to first-line atezolizumab in advanced NSCLC patients.
Former Vice President Joe Biden says pooling data on cancer patients is key to finding a cure — and is the focus of his cancer Moonshot initiative.
Roche-backed Foundation Medicine will bring its genomic sequencing of tumors to China in the third quarter.